Investigating how NLRP3 signaling affects inflammation and immune responses
Cryopyrin/NLRP3 Signaling in Inflammation and Innate Immunity
This study is looking at how a part of your immune system called the NLRP3 inflammasome can become too active and contribute to diseases like Alzheimer's and heart problems, with the hope of finding new ways to help manage these conditions.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10991794 on NIH RePORTER |
What this research studies
This research focuses on understanding the NLRP3 inflammasome, a key component in the body's immune response that can become overactive in various inflammatory diseases. The study aims to identify the mechanisms by which NLRP3 is activated and how it contributes to conditions like Alzheimer's disease and atherosclerosis. By examining the role of the Nek7 kinase and potassium efflux in this process, the research seeks to uncover new therapeutic targets that could help manage these diseases. Patients may benefit from insights that could lead to innovative treatments for inflammatory disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, atherosclerosis, or other inflammatory disorders linked to NLRP3 activation.
Not a fit: Patients with non-inflammatory conditions or those not affected by Alzheimer's or atherosclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that better manage or prevent inflammatory diseases, including Alzheimer's and atherosclerosis.
How similar studies have performed: Previous research has shown promising results in targeting the NLRP3 inflammasome for treating inflammatory diseases, suggesting that this approach has potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Nunez, Gabriel — University of Michigan at Ann Arbor
- Study coordinator: Nunez, Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.